Medicinal Chemistry Driven Approaches Toward Novel and Selective Serotonin 5-HT6 Receptor Ligands

Based on a medicinal chemistry guided hypothetical pharmacophore model, novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT6 receptor ligands. Furthermore, based on a screening approach of a discovery library, a series of benzoxazinepipe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry Vol. 48; no. 6; pp. 1781 - 1795
Main Authors: Holenz, Jörg, Mercè, Ramon, Díaz, José Luis, Guitart, Xavier, Codony, Xavier, Dordal, Alberto, Romero, Gonzalo, Torrens, Antoni, Mas, Josep, Andaluz, Blas, Hernández, Susana, Monroy, Xavier, Sánchez, Elisabeth, Hernández, Enrique, Pérez, Raquel, Cubí, Roger, Sanfeliu, Olga, Buschmann, Helmut
Format: Journal Article
Language:English
Published: Washington, DC American Chemical Society 24-03-2005
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Based on a medicinal chemistry guided hypothetical pharmacophore model, novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT6 receptor ligands. Furthermore, based on a screening approach of a discovery library, a series of benzoxazinepiperidinyl sulfonamides were identified as selective 5-HT6 ligands. Many of the compounds described in this paper possess excellent affinities, displaying pK i values greater than 8 (some even >9) and high selectivities against a wide range (>50) of other CNS relevant receptors. First, structure−affinity relationships of these ligands are discussed. In terms of functionality, high-affinity antagonists, as well as agonists and even partial agonists, were prepared. Compounds 19c and 19g represent the highest-affinity 5-HT6 agonists ever reported in the literature. These valuable tool compounds should allow for the detailed study of the role of the 5-HT6 receptor in relevant animal models of disorders such as cognition deficits, depression, anxiety, or obesity.
Bibliography:istex:D3D6680AFC020181140C81C26E6D427AC164011D
ark:/67375/TPS-S16GN1KG-G
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/jm049615n